Author:
Raimondo Paola,Casilli Giorgio,Isernia Martina,Lidonnici Dario,Ravasio Roberto,Ronco Virginia,Lanati Elena
Abstract
Objective. To compare the time-to-reimbursement of the last two committees of the Italian Medicines Agency (AIFA), respectively appointed in 2015 and in 2018.
Methods. The analysis was run through a specific internal database created by MA-Provider. The database was populated with information regarding European Medicines Agency (EMA) approved new drugs, including each step of the Italian Price and Reimbursement (P&R) process reported in the monthly outcomes of Technical Scientific Committee (CTS) and Price and Reimbursement Committee (CPR) meetings from September 2015 to April 2020.
Results. The 2015 and the 2018 committees have reimbursed respectively 39 and 28 drugs by comparing their initial 19 months of activity. Significant differences have been observed in negotiated economic conditions, in particular an increase in the number of drugs with confidential discount (2018-committee: 96.4% vs 2015-committee: 64.1%; p = 0.003) and a reduction in the application of Managed Entry Agreements (MEAs) (2018-committee: 10.7% vs 2015-committee: 33.3%; p = 0.036). The average duration of the P&R procedure managed by the 2018-committee has increased by 45 days compared to the 2015-committee (287 days vs 242 days; p = 0.071) and this trend of delay is associated to the active scientific/economic assessment phase by CTS and CPR (particularly by the latter) and not to administrative phases (e.g. Official Journal publications).
Conclusions. The observed differences between committees may be explained by the higher number of oncological and/or innovative drugs assessed by the 2018-committee (regarding the time delay, probably linked to greater difficulties in finding a win-win agreement able to satisfy both AIFA and Pharmaceutical Company).
Reference16 articles.
1. Bibliografia
2. 1. Lidonnici D, Ronco V, Isernia M, et al. Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: analisi delle tempistiche di valutazione dell'Agenzia Italiana del Farmaco. Global & Regional Health Technology Assessment. 2018:1-9. DOI: https://doi.org/10.33393/grhta.2018.433
3. 2. European Commission. Authorisation procedures - The centralised procedure. https://ec.europa.eu/health/authorisation-procedures-centralised_en (Data ultimo accesso: maggio 2020).
4. 3. European Medicines Agency (EMA). Il sistema normativo europeo per i medicinali. Un approccio unitario alla regolamentazione dei medicinali in tutta l'Unione Europea. https://www.ema.europa.eu/en/documents/leaflet/european-regulatory-system-medicines-european-medicines-agency-consistent-approach-medicines_it.pdf (2016. Data ultimo accesso: maggio 2020).
5. 4. European Federation of the Pharmaceutical Industries and Associations (EFPIA) Patient W.A.I.T. Indicator 2018 survey. https://www.efpia.eu/media/412747/efpia-patient-wait-indicator-study-2018-results-030419.pdf (2019. Data ultimo accesso: maggio 2020).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献